34231-77-1Relevant articles and documents
Triarylamine-based hydrido-carboxylate rhenium(i) complexes as photosensitizers for dye-sensitized solar cells
Veronese, Lorenzo,Quartapelle Procopio, Elsa,Moehl, Thomas,Panigati, Monica,Nonomura, Kazuteru,Hagfeldt, Anders
, p. 7534 - 7543 (2019)
Two new dyes based on a dinuclear rhenium complex and (E)-3-(5-(4-(bis(2′,4′-dibutoxy-[1,1′-biphenyl]-4-yl)amino)phenyl)thiophen-2-yl)-2-cyanoacrylic acid (namely D35) have been investigated as sensitizers for dye sensitized solar cells (DSSCs). Two different pyridazine ligands have been used, namely 4-pyridazine-carboxylic acid for dye 2 ([Re2(μ-H)(-D35)(CO)6(μ-pyridazine-4-COOH)]) and 4-pyridazinyl-butanoic acid for dye 3 ([Re2(μ-H)(-D35)(CO)6(μ-pyridazine-4-C3H6-COOH)]). The performances of these new dyes have been compared with those of the dye containing the bare 4-diphenylaminobenzoic acid, namely TPA, as the ancillary ligand (dye 1). Compared to dye 1, dyes 2 and 3 show an impressive tenfold increase in the absorption intensity in the range of 487-493 nm on TiO2 films, with great improvement of the light harvesting. Cyclic voltammetry experiments, performed on derivatives containing the methyl ester of the pyridazine ligands, show narrow electrochemical band gaps in the range of 1.36-1.84 eV. Solar cells with each dye have been prepared, using both iodide/triiodide and cobalt redox couples as the electrolytes, platinum or carbon as the counter electrodes, and TiO2 or SnO2 as the metal oxide photoelectrodes, respectively. The best DSSC results have been obtained using dye 3, with an overall solar-to-electric conversion efficiency of 3.5%, which greatly overcomes the previous result of 1.0% obtained for dye 1 in a not-optimized setup of the device. The performances of dye 3 are due to the presence of D35 ligand, which further suppresses the recombination of the injected electron with the electrolyte and with the oxidized state of the dye.
An anthrone-based Kv7.2/7.3 channel blocker with improved properties for the investigation of psychiatric and neurodegenerative disorders
Porter, Jacob D.,Vivas, Oscar,Weaver, C. David,Alsafran, Abdulmohsen,DiMilo, Elliot,Arnold, Leggy A.,Dickson, Eamonn J.,Dockendorff, Chris
supporting information, (2019/11/11)
A set of novel Kv7.2/7.3 (KCNQ2/3) channel blockers was synthesized to address several liabilities of the known compounds XE991 (metabolic instability and CYP inhibition) and the clinical compound DMP 543 (acid instability, insolubility, and lipophilicity). Using the anthrone scaffold of the prior channel blockers, alternative heteroarylmethyl substituents were installed via enolate alkylation reactions. Incorporation of a pyridazine and a fluorinated pyridine gave an analog (compound 18, JDP-107) with a promising combination of potency (IC50 = 0.16 μM in a Kv7.2 thallium flux assay), efficacy in a Kv7.2/7.3 patch clamp assay, and drug-like properties.
NOVEL 1,2,4 OXADIAZOLE COMPOUNDS AND METHODS OF USE THEREOF
-
Page/Page column 72-73, (2009/12/28)
The invention relates to 1,2,4 oxadiazole compounds and analogs thereof, represented by formula (II), and compositions and methods of use thereof.
